67 18. DESCRIPTION OF PROTO COL DRUGS OR DEVICES ................................68 18.1 Preparation and Administration of Standard of Care Therapeutic Agents .. 68 18.2 Cyclophosphamide ....................................................................................... 68 18.3 Mesna ........................................................................................................... 69 18.4 Etoposide ...................................................................................................... 70 18.5 Temozolomide (Temodar®) ......................................................................... 72 18.6 Carboplatin ................................................................................................... 73 18.7 Thiotepa ....................................................................................................... 75 18.8 Fludarabine phosphate ................................................................................. 76 19. PREPARATION, ADMINIS TRATION, AND TRANSPO RT OF EXPERIMENTAL THERAPEUTIC AGENTS (DC + XALT THERAPY) ..............77 19.1 External Sites ............................................................................................... 77 19.2 TTRNA isolation ......................................................................................... 77 19.3 Amplification of RNA ................................................................................. 77 19.4 Procedure for TTRNA -DC and TTRNA -xALT Generation ....................... 78 20.